Neuramis Deep No Lidocaine

Neuramis Deep No Lidocaine: High-Strength Monophasic HA Filler for Deep Volumization & Lift

Neuramis Deep No Lidocaine, manufactured by **LG Chem Life Sciences**, is a **premium, monophasic, non-animal stabilized hyaluronic acid (NASHA) dermal filler** formulated **without integrated anesthetic**. Presented in a **1.0 ml prefilled syringe**, it contains a **high concentration (23 mg/ml) of cross-linked HA** specifically engineered for **deep structural volumization, contouring, and lifting** of the mid and lower face. Its high elasticity and cohesivity make it ideal for restoring significant volume loss and providing strong projection where substantial support is needed.https://skin-reboot.com/

**Core Technology & Properties:**
* **Premixed Monophasic NASHA Gel:** Features a homogeneous, highly cross-linked (using BDDE) HA matrix for predictable tissue integration and long-lasting results. The monophasic structure ensures smooth flow.
* **No Lidocaine:** Purposely excludes local anesthetic, suitable for patients with sensitivities or practitioners preferring targeted topical anesthesia.
* **High G-Prime (Elasticity):** Exhibits **exceptional resistance to deformation**, enabling powerful lifting of sagging tissues and maintaining projection in deep tissue planes against gravitational forces.
* **High Cohesivity:** Gel particles bind tightly together, providing **strong structural integrity**, minimizing spread/migration, and optimizing lifting capacity.
* **High HA Concentration (23 mg/ml):** Delivers significant volumizing power per injection.
* **Optimized Particle Size:** Designed for durability and performance in deep subcutaneous and supraperiosteal layers.

**Mechanism of Action:**
1. **Structural Volumization & Lift:** High-cohesivity gel provides immediate projection and lift upon injection into deep facial planes, restoring volume deficits and recontouring sagging areas.
2. **Hydration:** HA binds water, improving tissue hydration.
3. **Biostimulation:** Stimulates gradual neocollagenesis and elastin production for sustained tissue quality improvement over time.

**Primary Indications:**
* **Midface Volumization & Lift:** Augmenting cheekbones, restoring malar volume, lifting nasolabial folds.
* **Jawline Definition & Contouring:** Enhancing mandibular projection and angle.
* **Chin Augmentation:** Adding anterior projection and improving profile.
* **Temporal Hollowing:** Restoring volume to sunken temples.
* **Deep Nasolabial Folds & Marionette Lines:** Correcting severe perioral folds requiring structural support.
* **Facial Rebalancing & Projection:** Enhancing overall facial harmony.

**Key Administration Considerations:**
* **Ready-to-Use:** No reconstitution required. Prime syringe according to instructions.
* **Anesthesia:** **Essential:** Requires effective topical numbing cream (e.g., LMX, EMLA) applied adequately before treatment due to deep injections and absence of integrated anesthetic. Consider regional nerve blocks.
* **Technique:** Primarily suited for **bolus/depot placement**:
* **Needles:** Sharp needles (e.g., 25-27G) for precise supraperiosteal injection.
* **Cannulas:** Highly compatible with blunt microcannulas (e.g., 22-25G, 50mm+) for deep subcutaneous/sub-SMAS placement, reducing vascular risks and bruising.
* **Depth:** **Deep subcutaneous tissue, supraperiosteal plane, or sub-SMAS layer.** *Avoid superficial injection.*
* **Volume:** Typically requires larger boluses (e.g., 0.2-0.5ml per point). Gradual build-up recommended.
* **Post-Treatment:** Expect significant **swelling** (can last several days), redness, tenderness, and potential bruising. Avoid pressure/massage.
* **Longevity:** Designed for **long-lasting results**, typically **12-18 months**, due to high HA concentration and cross-linking density.
* **Safety:** Standard filler risks: Swelling, bruising, redness, nodules, infection, hypersensitivity. **Critical Risk:** **Vascular occlusion** is possible due to deep placement; necessitates **expert anatomical knowledge**, aspiration, and preference for cannulas. Risk of visible nodules if placed too superficially or overcorrected. Tyndall effect unlikely at correct depth.
* **Regulatory Status:** **CE marked** (Europe/international). **Not FDA-approved in the USA.**
* **Prescription:** Prescription medical device.

Neuramis Deep No Lidocaine offers practitioners a potent, lidocaine-free solution for achieving significant structural facial restoration and lift, leveraging high-concentration, high-G prime monophasic HA technology for enduring deep-tissue volumization.CONTACT US